During its September 2024 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave the go-ahead for Penbraya (Pfizer) — meningococcal groups A, C, W, Y conjugate and group B vaccine — to be used to protect individuals from invasive meningococcal disease…
